BoomRx Centralizes Peptide Therapy Sourcing Amid Regulatory Shifts
Event summary
- BoomRx launched a centralized pharmacy portal for peptide therapies on March 18, 2026.
- The U.S. peptide therapeutics market was valued at $21 billion in 2025 and is projected to reach $35 billion by 2035.
- FDA is reviewing whether 14 peptides could return to regulated pharmaceutical supply chains.
- BoomRx consolidates multi-pharmacy workflows, simplifying state-by-state shipping and improving price transparency.
The big picture
BoomRx's centralized pharmacy portal addresses the operational complexity faced by medical practices as peptide therapies gain wider clinical adoption. The move comes amid evolving regulatory frameworks and a projected market growth to $35 billion by 2035. By consolidating sourcing and fulfillment, BoomRx aims to reduce administrative burden and support scalable care programs.
What we're watching
- Regulatory Clarity
- How FDA's review of 14 peptides will impact BoomRx's operational strategy and market positioning.
- Market Expansion
- The pace at which BoomRx can scale its centralized pharmacy portal to meet growing peptide therapy demand.
- Competitive Dynamics
- Whether BoomRx can sustain its growth as other platforms enter the peptide therapy sourcing space.
Related topics